Microbot Medical Inc.
Microbot Medical Inc. (MBOT) Financial Performance & Income Statement Overview
Analyze Microbot Medical Inc. (MBOT) financial statements (income, balance sheet, and cash flow) across both yearly and quarterly periods.
Microbot Medical Inc. (MBOT) Income Statement & Financial Overview
Access detailed annual and quarterly income data for Microbot Medical Inc. MBOT financial performance.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $26000.00 | $0.00 | $14000.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | -$14000.00 |
| Gross Profit Ratio | $0.00 | |||
| R&D Expenses | $1.46M | $1.96M | $2.06M | $1.42M |
| SG&A Expenses | $1.56M | $1.37M | $1.24M | $1.09M |
| Operating Expenses | $3.02M | $3.40M | $3.30M | $2.51M |
| Total Costs & Expenses | $0.00 | $3.43M | $3.30M | $2.51M |
| Interest Income | $0.00 | $38000.00 | $0.00 | $46000.00 |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $0.00 | $26000.00 | $23000.00 | $14000.00 |
| EBITDA | $0.00 | -$3.40M | -$3.28M | -$2.50M |
| EBITDA Ratio | ||||
| Operating Income | $0.00 | -$3.43M | -$3.30M | -$2.51M |
| Operating Income Ratio | ||||
| Other Income/Expenses (Net) | $0.00 | $38000.00 | $85000.00 | $46000.00 |
| Income Before Tax | $104000.00 | -$3.39M | -$3.21M | -$2.46M |
| Income Before Tax Ratio | ||||
| Income Tax Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | $104000.00 | -$3.39M | -$3.21M | -$2.46M |
| Net Income Ratio | ||||
| EPS | -$0.08 | -$0.22 | -$0.20 | -$0.17 |
| Diluted EPS | -$0.08 | -$0.22 | -$0.20 | -$0.17 |
| Weighted Avg Shares Outstanding | $31.09M | $17.02M | $16.47M | $14.85M |
| Weighted Avg Shares Outstanding (Diluted) | $31.09M | $17.02M | $16.47M | $14.85M |
Financial performance has remained strong, with revenue growing from $0.00 in Q2 2024 to $0.00 in Q1 2025. Gross profit continued to perform well, with margins at N/A in the latest quarter. Operating income reached $0.00 in Q1 2025, holding a steady N/A margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at $0.00. Net income rose to $104000.00, keeping EPS at -$0.08. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan